Evidence map›Paper›PMID 35929347›Full record

ArticleJournal of clinical laboratory analysis2022

Glucosamine-phosphate N-acetyltransferase 1 and its DNA methylation can be biomarkers for the diagnosis and prognosis of lung cancer.

Peikun Ding, Bin Peng, Guofeng Li, Xuefeng Sun, Guangsuo Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Peikun DingDepartment of Thoracic Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University.
Bin PengDepartment of Thoracic Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University.
Guofeng LiDepartment of Thoracic Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University.ORCID https://orcid.org/0000-0002-3806-0493
Xuefeng SunDepartment of Thoracic Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University.
Guangsuo WangDepartment of Thoracic Surgery, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University.
Jinan University · CN

Funding

Shenzhen Key Medical Discipline Construction Fund No.SZXK018
6 · The paper itself

Abstract

objectiveLung cancer ranking high in the cancer-related list has long perplexed patients, in which glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1) is found to be highly expressed. Besides, DNA methylation is perceived as a biomarker to assess the prognosis of patients with various cancers. However, the correlation between GNPNAT1 and DNA methylation and the role of GNPNAT1 in lung cancer remain vague.

methodsPrincipal component analysis (PCA), heatmap, volcano map, Venn diagram, gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to screen out the candidate genes. The viability, migration, and invasion of lung cancer cells were detected by CCK-8 and Transwell assays. An xenograft tumor mouse model was established. The relative expressions of GNPNAT1, E-cadherin, vimentin, Matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinase-2 (TIMP-2), E2F1, and cyclin D1 in cells or xenograft tumor tissues were quantified by Western blot, RT-qPCR, or immunohistochemistry assay.

resultsGNPNAT1 was screened as the research object. GNPNAT1 methylation was downregulated, while GNPNAT1 expression was upregulated in lung cancer tissues. The methylation and mRNA levels of GNPNAT1 were correlated with the patient prognosis. GNPNAT1 increased cell viability, migration and invasion, and promoted the xenograft tumor volume and weight, whereas shGNPNAT1 acted oppositely. Moreover, expressions of Vimentin, MMP-2, E2F1, and cyclin D1 were increased, but E-cadherin and TIMP-2 expressions were decreased by overexpressed GNPNAT1, whilst GNPNAT1 knockdown ran conversely.

conclusionGNPNAT1 and methylated GNPNAT1 coverage are biomarkers for the diagnosis and prognosis of lung cancer.

Indexed as

Lung NeoplasmsMatrix Metalloproteinase 2AnimalsCadherinsCell Line, TumorCell ProliferationCyclin D1DNA MethylationGene Expression Regulation, NeoplasticGlucosamine 6-Phosphate N-AcetyltransferaseHumansMicePrognosisTissue Inhibitor of Metalloproteinase-2VimentinCadherinsCyclin D1Glucosamine 6-Phosphate N-AcetyltransferaseGNPNAT1 protein, humanMatrix Metalloproteinase 2Tissue Inhibitor of Metalloproteinase-2VimentinBiomarkerDNA methylationGNPNAT1Lung cancerPrognosis

Identifiers

PMID35929347
PMCPMC9459321
OpenAlexW4289861523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.